View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	ACAD
Entity Registrant Name	ACADIA PHARMACEUTICALS INC
Entity Central Index Key	0001070494
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		99,770,300

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2014

Dec. 31, 2013

^[1]

Assets

Cash and cash equivalents

$ 36,369

$ 11,707

Investment securities, available-for-sale

301,430

174,083

Interest and other receivables

1,139

750

Prepaid expenses and other current assets

2,127

1,820

Total current assets

341,065

188,360

Property and equipment, net

520

579

Other assets

178

179

Total assets

341,763

189,118

Liabilities and stockholders' equity

Accounts payable

1,110

372

Accrued expenses

10,128

6,552

Deferred revenue

Total current liabilities

11,253

6,979

Long-term liabilities

Total liabilities

11,274

6,987

Commitments and contingencies (Note 9)

Stockholders' equity

Preferred stock, $0.0001 par value; 5,000,000 shares authorized at September 30, 2014 and December 31, 2013; no shares issued and outstanding at September 30, 2014 and December 31, 2013

Common stock, $0.0001 par value; 150,000,000 shares authorized at September 30, 2014 and December 31, 2013; 99,701,621 shares and 91,102,618 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively

Additional paid-in capital

800,179

587,742

Accumulated deficit

(469,777)

(405,668)

Accumulated other comprehensive income

Total stockholders' equity

330,489

182,131

Total liabilities and stockholders' equity

$ 341,763

$ 189,118

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Sep. 30, 2014

Dec. 31, 2013

^[1]

Statement of Financial Position [Abstract]

Preferred stock, par value

$ 0.0001

Preferred stock, shares authorized

5,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value

$ 0.0001

Common stock, shares authorized

150,000,000

Common stock, shares issued

99,701,621

91,102,618

Common stock, shares outstanding

99,701,621

91,102,618

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues
Collaborative revenues	$ 15	$ 240	$ 72	$ 1,108
Operating expenses
Research and development (includes stock-based compensation expense of $1,358, $690, $3,452, and $1,417, respectively)	16,952	7,254	42,420	18,797
General and administrative (includes stock-based compensation expense of $2,544, $1,201, $7,942, and $2,120, respectively)	8,057	3,797	22,328	8,444
Total operating expenses	25,009	11,051	64,748	27,241
Loss from operations	(24,994)	(10,811)	(64,676)	(26,133)
Interest income, net	208	116	567	234
Net loss	$ (24,786)	$ (10,695)	$ (64,109)	$ (25,899)
Net loss per common share, basic and diluted	$ (0.25)	$ (0.12)	$ (0.66)	$ (0.31)
Weighted average common shares outstanding, basic and diluted	99,497	89,504	97,210	83,946

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock-based compensation expense			$ 11,394	$ 3,537
Research and development
Stock-based compensation expense	$ 1,358	$ 690	3,452	1,417
General and administrative
Stock-based compensation expense	$ 2,544	$ 1,201	$ 7,942	$ 2,120

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]
Net loss	$ (24,786)	$ (10,695)	$ (64,109)	$ (25,899)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	(17)	110	29	80
Comprehensive loss	$ (24,803)	$ (10,585)	$ (64,080)	$ (25,819)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Cash flows from operating activities

Net loss

$ (64,109)

$ (25,899)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation

11,394

3,537

Amortization of premiums on investment securities

345

938

Depreciation

145

Gain on disposal of assets

(10)

Changes in operating assets and liabilities:

Interest and other receivables

(389)

(716)

Prepaid expenses and other current assets

(307)

(1,198)

Other assets

(120)

Accounts payable

738

(255)

Accrued expenses

3,576

2,531

Deferred revenue

(40)

(354)

Long-term liabilities

Net cash used in operating activities

(48,633)

(21,504)

Cash flows from investing activities

Purchases of investment securities

(307,211)

(186,756)

Maturities of investment securities

179,548

51,589

Purchases of property and equipment

(86)

(490)

Proceeds from sales of property and equipment

Net cash used in investing activities

(127,749)

(135,645)

Cash flows from financing activities

Proceeds from issuance of common stock, net of issuance costs

201,044

111,053

Net cash provided by financing activities

201,044

111,053

Net increase (decrease) in cash and cash equivalents

24,662

(46,096)

Cash and cash equivalents

Beginning of period

11,707

^[1]

57,899

End of period

$ 36,369

$ 11,803

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2014
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of ACADIA Pharmaceuticals Inc. should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (the “SEC”). The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates. The Company has incurred substantial operating losses since its inception due in large part to expenditures for its research and development activities. As of September 30, 2014, the Company had an accumulated deficit of $469.8 million. The Company expects to continue to incur operating losses for at least the next few years as it pursues the development and commercialization of its product candidates. The Company may require significant additional financing in the future to fund its operations. Future capital requirements will depend on many factors, including the progress in, the outcome of and the costs of the Company’s development and regulatory activities, including the ability of the Company to obtain regulatory approval for its products, costs associated with establishing necessary sales and marketing capabilities, the amount of product sales, if any, the scope, prioritization and number of its research and development programs, the ability of its collaborators and the Company to reach milestones and other events or developments under its collaboration and license agreements, and the ability of the Company to enter into new, and to maintain existing, collaboration and license agreements. Unless and until the Company can generate significant cash from operations, it expects to fund its operations through its existing cash, cash equivalents and investment securities, payments from existing and potential future collaborations, proceeds from public or private sales of its equity securities, debt financing, grant funding, or by licensing all or a portion of its product candidates or technology. The Company cannot be certain that adequate additional funding will be available on acceptable terms, or at all. Conditions in the financial markets and other factors could have a material adverse effect on the Company’s ability to access sufficient funding on acceptable terms, or at all. If the Company needs but cannot raise adequate additional capital, it will be required to delay, reduce the scope of, or eliminate one or more of its research or development programs or its commercialization efforts. In such circumstances, the Company may also be required to relinquish greater, or even all, rights to product candidates at earlier stages of development or commercialization or on less favorable terms than it would otherwise choose.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Net Loss Per Share

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Net Loss Per Share

2. Net Loss Per Share

Net loss per share is presented as basic and diluted net loss per share. Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options and warrants are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.

Shares used in calculating basic and diluted net loss per common share exclude the following potential common shares as their effect is antidilutive (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Antidilutive options to purchase common stock		7,787		7,448		7,733		7,220
Antidilutive warrants to purchase common stock		1,966		3,075		1,966		3,505

		9,753		10,523		9,699		10,725

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	3. Stock-Based Compensation The fair value of each stock option and each employee stock purchase plan right granted is estimated on the grant date under the fair value method using the Black-Scholes valuation model. The estimated fair values of the stock options or purchase plan rights, including the effect of estimated forfeitures, are then expensed over the vesting period. During the first quarter of 2014, the Board of Directors approved modifications to the Company’s former Chief Financial Officer’s outstanding stock options in connection with his retirement from the Company on April 18, 2014. Stock-based compensation expense for the nine months ended September 30, 2014 included $1.7 million related to the modification of the stock options held by the Company’s former Chief Financial Officer. No stock-based compensation expense was incurred for this modification during the three months ended September 30, 2014. As of September 30, 2014, total unrecognized compensation cost related to stock options and purchase plan rights was approximately $43.6 million, which is expected to be recognized over a weighted-average period of 2.9 years.

Accrued Expenses

9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accrued Expenses

4. Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	September 30, 2014		December 31, 2013
Accrued research and development services	$	6,334	$	4,207
Accrued compensation and benefits		2,466		1,865
Accrued consulting and professional fees		1,160		308
Other		168		172

	$	10,128	$	6,552

Investment Securities

9 Months Ended

Sep. 30, 2014

Investments, Debt and Equity Securities [Abstract]

Investment Securities

5. Investment Securities

Investment securities, all classified as available-for-sale, consisted of the following (in thousands):


	September 30, 2014
	Amortized Cost		Unrealized Gains		Unrealized (Losses)			Estimated Fair Value
U.S. Treasury notes	$	2,747	$	4	$	—		$	2,751
Government sponsored enterprise securities		125,537		38		(3	)		125,572
Corporate debt securities		150,113		31		(35	)		150,109
Commercial paper		22,961		37		—			22,998

	$	301,358	$	110	$	(38	)	$	301,430


	December 31, 2013
	Amortized Cost		Unrealized Gains		Unrealized (Losses)			Estimated Fair Value
U.S. Treasury notes	$	2,743	$	4	$	—		$	2,747
Government sponsored enterprise securities		78,537		28		(5	)		78,560
Corporate debt securities		65,290		1		(9	)		65,282
Commercial paper		27,468		26		—			27,494

	$	174,038	$	59	$	(14	)	$	174,083

The Company has classified all of its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2014 and December 31, 2013, the Company held $11.1 million and $33.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

6. Fair Value Measurements

As of September 30, 2014, the Company held $337.4 million of cash equivalents and available-for-sale investment securities consisting of a money market fund, U.S. Treasury notes, and high quality, marketable debt instruments of corporations, financial institutions and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A3/A- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s.

The Company’s cash equivalents and available-for-sale investment securities are classified within the fair value hierarchy as defined by authoritative guidance. The Company’s investment securities classified as Level 1 are valued using quoted market prices and the Company’s investment securities classified as Level 2 are valued using other observable inputs such as recent trades for the securities or similar securities, interest rates on similar securities, or yield curves or benchmark interest rates observable at commonly quoted intervals. The Company does not hold any securities classified as Level 3, which are securities valued using unobservable inputs. The Company has not transferred any investment securities between the classifications. No other-than-temporary impairments were identified for the investment securities held by the Company as of September 30, 2014 or December 31, 2013.

The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):


			Fair Value Measurements at Reporting Date Using
	September 30, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market fund	$	35,935	$	35,935	$	—	$	—
U.S. Treasury notes		2,751		2,751		—		—
Government sponsored enterprise securities		125,572		—		125,572		—
Corporate debt securities		150,109		—		150,109		—
Commercial paper		22,998		—		22,998		—

	$	337,365	$	38,686	$	298,679	$	—


			Fair Value Measurements at Reporting Date Using
	December 31, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market fund	$	11,748	$	11,748	$	—	$	—
U.S. Treasury notes		2,747		2,747		—		—
Government sponsored enterprise securities		78,560		—		78,560		—
Corporate debt securities		65,282		—		65,282		—
Commercial paper		27,494		—		27,494		—

	$	185,831	$	14,495	$	171,336	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2014
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity In March 2014, the Company raised net proceeds of $196.8 million from the sale of 7,360,000 shares of its common stock in a public offering, including 960,000 shares sold pursuant to the exercise in full of the underwriters’ over-allotment option.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Collaborative Research and Licensing Agreements	9 Months Ended
Collaborative Research and Licensing Agreements	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Research and Licensing Agreements	8. Collaborative Research and Licensing Agreements The Company has been a party to three collaboration agreements with Allergan, Inc. The March 2003 research collaboration originally provided for a three-year research term, which was extended by the parties through March 2013. Pursuant to this agreement, the Company received an aggregate of $19.5 million in payments, consisting of an upfront payment, research funding and related fees, through the conclusion of the collaboration in March 2013. The Company’s two ongoing collaboration agreements with Allergan involve the development of product candidates in the areas of glaucoma and chronic pain. Additional payments under these agreements, other than payments for a portion of patent costs for the ongoing collaborations, are dependent upon the successful advancement of an applicable product candidate. Under the glaucoma collaboration, the Company had received from commencement of the collaboration an aggregate of $9.9 million in payments as of September 30, 2014, and is eligible to receive up to an aggregate of approximately $15 million in additional payments per product upon the achievement of development and regulatory milestones. Under the chronic pain collaboration, the Company had received from commencement of the collaboration an aggregate of $10.5 million in payments as of September 30, 2014, and is eligible to receive up to an aggregate of $10 million in additional payments upon the achievement of development and regulatory milestones. The Company also is eligible to receive royalties on future product sales worldwide, if any, under each of the two ongoing collaboration agreements with Allergan. The Company recognized revenues, consisting of research funding and related fees, from its collaboration agreements with Allergan of $1,000 and $23,000 during the three and nine months ended September 30, 2014, respectively, and $15,000 and $559,000 during the three and nine months ended September 30, 2013, respectively.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies The Company has entered into agreements with contract research organizations and other external service providers primarily for services in connection with the development and planned commercialization of its product candidates. The Company was contractually obligated for up to approximately $19.3 million of future services under these agreements as of September 30, 2014. The nature of the work being conducted under the Company’s agreements with external service providers is such that, in most cases, the services may be stopped with short notice. In such event, the Company would not be liable for the full amount of the contract. The Company’s actual contractual obligations may vary depending upon several factors, including the progress and results of the underlying studies. In connection with the Company’s 2006 license agreement with the Ipsen Group, the Company may be obligated in future periods to make certain regulatory milestone payments. These milestone payments may never occur as they are contingent on the achievement of future regulatory events which may never be attained. As of September 30, 2014, the total of these potential future regulatory milestone payments was $10.5 million.

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2014
New Accounting Pronouncement or Change in Accounting Principle, Current Period Disclosures [Abstract]
Recent Accounting Pronouncements	10. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company will adopt this guidance on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements and related disclosures. In August 2014, the FASB issued authoritative accounting guidance related to an entity’s ability to continue as a going concern. This guidance will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The new standard is effective for annual reporting periods ending after December 15, 2016 and early adoption is permitted. The Company intends to adopt this guidance at the beginning of its first quarter of fiscal year 2016 and does not expect it to have a material impact on its consolidated financial statements and related disclosures.

Stock-Based Compensation (Policies)	9 Months Ended
Stock-Based Compensation (Policies)	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	The fair value of each stock option and each employee stock purchase plan right granted is estimated on the grant date under the fair value method using the Black-Scholes valuation model. The estimated fair values of the stock options or purchase plan rights, including the effect of estimated forfeitures, are then expensed over the vesting period.

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Potential Common Shares Excluded in Calculating Basic and Diluted Net Loss Per Common Share

Shares used in calculating basic and diluted net loss per common share exclude the following potential common shares as their effect is antidilutive (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Antidilutive options to purchase common stock		7,787		7,448		7,733		7,220
Antidilutive warrants to purchase common stock		1,966		3,075		1,966		3,505

		9,753		10,523		9,699		10,725

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	September 30, 2014		December 31, 2013
Accrued research and development services	$	6,334	$	4,207
Accrued compensation and benefits		2,466		1,865
Accrued consulting and professional fees		1,160		308
Other		168		172

	$	10,128	$	6,552

Investment Securities (Tables)

9 Months Ended

Sep. 30, 2014

Investments, Debt and Equity Securities [Abstract]

Investment Securities, All Classified as Available-for-Sale

Investment securities, all classified as available-for-sale, consisted of the following (in thousands):


	September 30, 2014
	Amortized Cost		Unrealized Gains		Unrealized (Losses)			Estimated Fair Value
U.S. Treasury notes	$	2,747	$	4	$	—		$	2,751
Government sponsored enterprise securities		125,537		38		(3	)		125,572
Corporate debt securities		150,113		31		(35	)		150,109
Commercial paper		22,961		37		—			22,998

	$	301,358	$	110	$	(38	)	$	301,430


	December 31, 2013
	Amortized Cost		Unrealized Gains		Unrealized (Losses)			Estimated Fair Value
U.S. Treasury notes	$	2,743	$	4	$	—		$	2,747
Government sponsored enterprise securities		78,537		28		(5	)		78,560
Corporate debt securities		65,290		1		(9	)		65,282
Commercial paper		27,468		26		—			27,494

	$	174,038	$	59	$	(14	)	$	174,083

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements of Cash Equivalents and Available-For-Sale Investment Securities

The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):


			Fair Value Measurements at Reporting Date Using
	September 30, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market fund	$	35,935	$	35,935	$	—	$	—
U.S. Treasury notes		2,751		2,751		—		—
Government sponsored enterprise securities		125,572		—		125,572		—
Corporate debt securities		150,109		—		150,109		—
Commercial paper		22,998		—		22,998		—

	$	337,365	$	38,686	$	298,679	$	—


			Fair Value Measurements at Reporting Date Using
	December 31, 2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market fund	$	11,748	$	11,748	$	—	$	—
U.S. Treasury notes		2,747		2,747		—		—
Government sponsored enterprise securities		78,560		—		78,560		—
Corporate debt securities		65,282		—		65,282		—
Commercial paper		27,494		—		27,494		—

	$	185,831	$	14,495	$	171,336	$	—

Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands

Sep. 30, 2014

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Accumulated deficit

$ (469,777)

$ (405,668)

^[1]

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Potential Common Shares Excluded in Calculating Basic and Diluted Net Loss Per Common Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities to purchase common stock	9,753	10,523	9,699	10,725
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities to purchase common stock	7,787	7,448	7,733	7,220
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities to purchase common stock	1,966	3,075	1,966	3,505

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense		$ 11,394,000	$ 3,537,000
Unrecognized compensation costs	$ 43,600,000	$ 43,600,000
Weighted-average period to be recognized		2 years 10 months 24 days
Former Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 0	$ 1,700,000
Retirement date		Apr. 18, 2014

Accrued Expenses (Detail) - USD ($)
$ in Thousands

Sep. 30, 2014

Dec. 31, 2013

Payables and Accruals [Abstract]

Accrued research and development services

$ 6,334

$ 4,207

Accrued compensation and benefits

2,466

1,865

Accrued consulting and professional fees

1,160

308

Other

168

172

Total

$ 10,128

$ 6,552

^[1]

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Investment Securities, All Classified as Available-for-Sale (Detail) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Schedule of Investments [Line Items]
Amortized Cost	$ 301,358	$ 174,038
Unrealized Gains	110	59
Unrealized (Losses)	(38)	(14)
Estimated Fair Value	301,430	174,083
U.S. Treasury notes
Schedule of Investments [Line Items]
Amortized Cost	2,747	2,743
Unrealized Gains	4	4
Estimated Fair Value	2,751	2,747
Government sponsored enterprise securities
Schedule of Investments [Line Items]
Amortized Cost	125,537	78,537
Unrealized Gains	38	28
Unrealized (Losses)	(3)	(5)
Estimated Fair Value	125,572	78,560
Corporate debt securities
Schedule of Investments [Line Items]
Amortized Cost	150,113	65,290
Unrealized Gains	31	1
Unrealized (Losses)	(35)	(9)
Estimated Fair Value	150,109	65,282
Commercial paper
Schedule of Investments [Line Items]
Amortized Cost	22,961	27,468
Unrealized Gains	37	26
Estimated Fair Value	$ 22,998	$ 27,494

Investment Securities - Additional Information (Detail) - USD ($)
$ in Thousands

Sep. 30, 2014

Dec. 31, 2013

Schedule of Investments [Line Items]

Available-for-sale investment securities

$ 301,430

$ 174,083

^[1]

Maturity Dates More Than 1 and Less Than 2 Years

Schedule of Investments [Line Items]

Available-for-sale investment securities

$ 11,100

$ 33,500

[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Investment, fair value disclosure	$ 337,365	$ 185,831
Impairment of investment securities	$ 0	$ 0

Fair Value Measurements of Cash Equivalents and Available-For-Sale Investment Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value disclosure	$ 337,365	$ 185,831
Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value disclosure	35,935	11,748
U.S. Treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	2,751	2,747
Government sponsored enterprise securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	125,572	78,560
Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	150,109	65,282
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	22,998	27,494
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value disclosure	38,686	14,495
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value disclosure	35,935	11,748
Quoted Prices in Active Markets for Identical Assets (Level 1) \| U.S. Treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	2,751	2,747
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value disclosure	298,679	171,336
Significant Other Observable Inputs (Level 2) \| Government sponsored enterprise securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	125,572	78,560
Significant Other Observable Inputs (Level 2) \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	150,109	65,282
Significant Other Observable Inputs (Level 2) \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities, fair value disclosure	$ 22,998	$ 27,494

Stockholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013
Class of Stock [Line Items]
Proceeds from sale of common stock	$ 196,800	$ 201,044	$ 111,053
Share of common stock issued	7,360,000
Underwriter
Class of Stock [Line Items]
Share of common stock issued	960,000

Collaborative Research and Licensing Agreements - Additional Information (Detail) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)	Sep. 30, 2014 USD ($) Contract	Sep. 30, 2013 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, revenues recognized	$ 15	$ 240		$ 72	$ 1,108
Allergan, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total number of collaboration agreements \| Contract				3
Number of ongoing collaboration agreements \| Contract				2
Collaboration agreement, revenues recognized	1	$ 15		$ 23	$ 559
Allergan, Inc. \| March 2003 Research Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, payments received			$ 19,500
Collaboration agreement, original research term			3 years
Collaboration agreement, termination date			2013-03
Collaboration agreement, beginning date			2003-03
Allergan, Inc. \| Glaucoma Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, payments received				9,900
Collaboration agreement, estimated development and regulatory milestones	15,000			15,000
Allergan, Inc. \| Chronic Pain Collaboration
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement, payments received				10,500
Collaboration agreement, estimated development and regulatory milestones	$ 10,000			$ 10,000

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 30, 2014 USD ($)
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Potential future regulatory milestone payments related to agreement with Ipsen Group	$ 10.5
Maximum
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Development services	$ 19.3